Autoinjectors Market Size, Trends & Forecast – Reaching $3.02 Billion by 2030

Autoinjectors Market Projected to Reach USD 3.02 Billion by 2030, Driven by Growing Demand for Self-Administration and Biologics Delivery

The latest report titled “Autoinjectors Market by Usage (Disposable, Reusable), Technology (Manual, Automatic), Therapy (Rheumatoid Arthritis, Diabetes, Obesity, Anaphylaxis, Multiple Sclerosis), Route of Administration (SC, IM), Volume (<3ml, >3ml) – Global Forecast to 2030” estimates that the global autoinjectors market will grow from USD 1.40 billion in 2024 to USD 3.02 billion by 2030, at a CAGR of 13.6%.

In addition, the autoinjector finished formulations market is expected to expand from USD 67.30 billion in 2024 to USD 134.27 billion by 2030, registering a CAGR of 12.2%.

Key Growth Drivers

The market’s growth is primarily driven by:

Favorable reimbursement policies.
Increasing regulatory approvals for autoinjectors.
Rising demand for self-administration of biologics.
Growing prevalence of chronic diseases, such as diabetes and rheumatoid arthritis.
Shift toward patient-centric drug delivery and increased adoption of prefilled autoinjectors for enhanced convenience and safety.
Strategic partnerships between pharmaceutical companies and device manufacturers.

The report includes 527 market data tables and 75 figures spread across 382 pages.
View the detailed Table of Contents here: https://www.marketsandmarkets.com/Market-Reports/autoinjector-market-173991724.html

Rheumatoid Arthritis Dominated the Market in 2023, with Obesity Segment Poised for Fastest Growth

By therapy, the autoinjectors market is segmented into:

Rheumatoid Arthritis
Multiple Sclerosis
Anaphylaxis
Diabetes
Obesity
Other therapies

In 2023, rheumatoid arthritis held the largest market share, driven by its high prevalence and the wide availability of autoinjectors for its treatment.

Meanwhile, the obesity segment is expected to grow at the fastest CAGR during the forecast period, supported by the launch of novel products and the increasing adoption of autoinjectors for weight management therapies. Notably, Wegovy (semaglutide) will be available in Australia starting August 2024, according to Australia’s Therapeutic Goods Administration.

Reusable Autoinjectors Expected to See Strong Growth Through 2030

By usage, the market is divided into:

Reusable autoinjectors
Disposable autoinjectors

In 2023, disposable autoinjectors led the market, driven by their ease of use, growing adoption in self-administration, and reduced risk of cross-contamination. However, reusable autoinjectors are projected to grow significantly during 2024-2030, fueled by advancements such as ergonomic designs, digital interfaces, and enhanced safety features, particularly in developing countries.

Europe: The Second-Largest Regional Market

Europe held the second-largest share of the global autoinjectors market, thanks to:

Supportive reimbursement and regulatory environments.
Increasing adoption of biologics and biosimilars, aided by EMA approvals.
Rising prevalence of chronic diseases.
Technological innovations, such as smart autoinjectors with digital connectivity.

Key players driving the European market include SHL Medical and Ypsomed.